IDUA and Scheie syndrome: Researchers from Samabriva, SA Company, France, investigated the capacity of B. rapa HRs for producing the recombinant protein alpha-L-iduronidase (IDUA), clinically important as an enzyme-replacement pharmaceutical for treating mucopolysaccharidosis type I (MPS I), a progressive lysosomal storage disorder.